These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 8807660)

  • 1. A fluvoxamine-caffeine interaction study.
    Jeppesen U; Loft S; Poulsen HE; Brśen K
    Pharmacogenetics; 1996 Jun; 6(3):213-22. PubMed ID: 8807660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro.
    Rasmussen BB; Nielsen TL; Brøsen K
    Pharmacol Toxicol; 1998 Dec; 83(6):240-5. PubMed ID: 9868741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Griseofulvin and fluvoxamine interactions with the metabolism of theophylline.
    Rasmussen BB; Jeppesen U; Gaist D; Brøsen K
    Ther Drug Monit; 1997 Feb; 19(1):56-62. PubMed ID: 9029748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of correlation between fluvoxamine clearance and CYP1A2 activity as measured by systemic caffeine clearance.
    Spigset O; Hägg S; Söderström E; Dahlqvist R
    Eur J Clin Pharmacol; 1999 Feb; 54(12):943-6. PubMed ID: 10192755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
    Christensen M; Tybring G; Mihara K; Yasui-Furokori N; Carrillo JA; Ramos SI; Andersson K; Dahl ML; Bertilsson L
    Clin Pharmacol Ther; 2002 Mar; 71(3):141-52. PubMed ID: 11907488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
    Ozdemir V; Naranjo CA; Shulman RW; Herrmann N; Sellers EM; Reed K; Kalow W
    J Clin Psychopharmacol; 1998 Jun; 18(3):198-207. PubMed ID: 9617978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.
    Jeppesen U; Gram LF; Vistisen K; Loft S; Poulsen HE; Brøsen K
    Eur J Clin Pharmacol; 1996; 51(1):73-8. PubMed ID: 8880055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.
    Jeppesen U; Rasmussen BB; Brøsen K
    Clin Pharmacol Ther; 1997 Sep; 62(3):279-86. PubMed ID: 9333103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
    Rasmussen BB; Brøsen K
    Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.
    Culm-Merdek KE; von Moltke LL; Harmatz JS; Greenblatt DJ
    Br J Clin Pharmacol; 2005 Nov; 60(5):486-93. PubMed ID: 16236038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The major fluvoxamine metabolite in urine is formed by CYP2D6.
    Spigset O; Axelsson S; Norström A; Hägg S; Dahlqvist R
    Eur J Clin Pharmacol; 2001 Nov; 57(9):653-8. PubMed ID: 11791895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.
    Lobo ED; Bergstrom RF; Reddy S; Quinlan T; Chappell J; Hong Q; Ring B; Knadler MP
    Clin Pharmacokinet; 2008; 47(3):191-202. PubMed ID: 18307373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2.
    Kinzig-Schippers M; Fuhr U; Zaigler M; Dammeyer J; Rüsing G; Labedzki A; Bulitta J; Sörgel F
    Clin Pharmacol Ther; 1999 Mar; 65(3):262-74. PubMed ID: 10096258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping.
    Kashuba AD; Nafziger AN; Kearns GL; Leeder JS; Gotschall R; Rocci ML; Kulawy RW; Beck DJ; Bertino JS
    Clin Pharmacol Ther; 1998 Sep; 64(3):257-68. PubMed ID: 9757149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
    Li Y; Liu L; Wang X; Zhang C; Reyes J; Hoffmann M; Palmisano M; Zhou S
    J Clin Pharmacol; 2018 Oct; 58(10):1295-1304. PubMed ID: 29762875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.
    Orlando R; Piccoli P; De Martin S; Padrini R; Floreani M; Palatini P
    Clin Pharmacol Ther; 2004 Jan; 75(1):80-8. PubMed ID: 14749694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide.
    Madsen H; Enggaard TP; Hansen LL; Klitgaard NA; Brøsen K
    Clin Pharmacol Ther; 2001 Jan; 69(1):41-7. PubMed ID: 11180037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity.
    Carrillo JA; Dahl ML; Svensson JO; Alm C; Rodríguez I; Bertilsson L
    Clin Pharmacol Ther; 1996 Aug; 60(2):183-90. PubMed ID: 8823236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 1A2.
    Brøsen K
    Clin Pharmacokinet; 1995; 29 Suppl 1():20-5. PubMed ID: 8846619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans.
    Becquemont L; Ragueneau I; Le Bot MA; Riche C; Funck-Brentano C; Jaillon P
    Clin Pharmacol Ther; 1997 Jun; 61(6):619-27. PubMed ID: 9209244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.